RLYB - רווח נקי למניה (EPS TTM) Rallybio Corp

Will software robots and data automation accelerate drug development? Rallybio Corporation (RLYB) is creating breakthrough treatments for rare immune pathologies in infants through antibody bioengineering. Flexibility is ensured via the complete outsourcing of production and testing. This chart on GURU.Markets reveals that the current annual net income per share, via the value 4.52, reflects the company's current financial health trend.
פילוחים אנליטיים של חברת Rallybio Corp. (RLYB)

Net income per share over 12 months determines the real efficiency of the business by comparing total income with the volume of issuance. This metric measures the company's ability to generate shareholder value after deducting all operating expenses. By analyzing the current level of annual net income per share, an investor assesses the capital's resilience to market volatility. For Rallybio Corporation (RLYB), this balance is supported by the stable operation of research centers. The timely modernization of contract lines for the production of orphan drugs minimizes the risks of a sharp decline in this indicator.